Methamphetamine-Induced Neurotoxicity and Parkinson's Disease Mechanisms

Methamphetamine is a potent psychostimulant whose abuse has been linked to long-term damage of dopaminergic neurons in the nigrostriatal pathway. At high concentrations, it promotes excessive cytosolic dopamine accumulation, impairs vesicular storage and generates reactive oxygen species, triggering mitochondrial dysfunction and oxidative stress. These events converge on protein homeostasis systems, favouring misfolding and aggregation of alpha-synuclein into Lewy-body-like inclusions. Concurrent neuroinflammatory responses amplify neuronal injury and may accelerate pathways implicated in idiopathic Parkinson’s disease. Genetic factors such as Parkin and Nurr1 modulate vulnerability by regulating ubiquitin-proteasome or transcriptional programmes essential for dopaminergic survival. Emerging evidence suggests that methamphetamine and Parkinson’s disease share common cellular insults—proteostatic failure, chronic inflammation and excitotoxicity—offering a framework for cross-disease therapeutic strategies. This has profound global significance given rising stimulant misuse and the increasing burden of neurodegenerative disorders. Translational applications include early biomarkers of aggregated proteins, repurposing of autophagy enhancers, antioxidant therapies and lifestyle interventions to mitigate both methamphetamine-related neurotoxicity and Parkinsonian progression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Methamphetamine-Induced Neurotoxicity and Parkinson's Disease Mechanisms publication trend

The graph below shows the total number of articles in methamphetamine-induced neurotoxicity and parkinson's disease mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-synuclein: A presynaptic neuronal protein prone to misfolding and aggregation in Parkinson’s disease and methamphetamine neurotoxicity.

Lewy body: Intracellular inclusion composed chiefly of aggregated alpha-synuclein and associated proteins, characteristic of Parkinson’s disease pathology.

Autophagy-lysosome pathway: Cellular degradation system whereby cytosolic components are sequestered in autophagosomes and delivered to lysosomes for recycling.

Ubiquitin-proteasome system: Proteolytic pathway that tags damaged or misfolded proteins with ubiquitin chains for degradation by the proteasome.

Dopaminergic neuron: Neuron that synthesises and releases dopamine, critically involved in motor control and particularly vulnerable in Parkinsonian disorders.

References

1. Combined light and electron microscopy (CLEM) to quantify methamphetamine-induced alpha-synuclein-related pathology. Journal of Neural Transmission (2024).
2. Decreased Level of Nurr1 in Heterozygous Young Adult Mice Leads to Exacerbated Acute and Long-Term Toxicity after Repeated Methamphetamine Exposure. PLOS ONE (2010).
3. Effect of Parkin on methamphetamine‐induced α‐synuclein degradation dysfunction in vitro and in vivo. Brain and Behavior (2020).
4. Aerobic Exercise Improves Methamphetamine-Induced Olfactory Dysfunction Through α-Synuclein Intervention in Male Mice. Frontiers in Molecular Neuroscience (2022).
5. Aggregation-prone A53T mutant of α-synuclein exaggerates methamphetamine neurotoxicity in SH-SY5Y cells: Protective role of cellular cholesterol. Toxicology Reports (2022).